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FOREWORD
Spaceflight incorporatesunique environmental factors to which organismshave not been
exposedin the courseof their phylogeneticdevelopment. Any observed physiological
response in the normal astronaut population is actually the result of the combination or
integration of the responses from several different body systems, each responding
simultaneously to the challenges of space flight and weightlessness. Some of the major
physiological changes induced by weightlessness are fluid shifts, electrolyte balance
changes, and hormonal and metabolic changes, including carbohydrate, protein, and fat
utilization. While it is apparent that space flight incurs marked physiological changes, the
effect of these changes on other physiology-dependent dynamic processe s like the
pharmacokinetics and pharmacodynamics of therapeutic agents is not clearly understood.
Pharmacological intervention to control pathophysiologic disorders occurring during space
flight will likely increase with the advent of extended duration missions on the Space
Shuttle and on Space Station Freedom. In order to ensure safe and effective therapeutic
intervention in space, it is important to understand the clinical pharmacology of
medications administered to crewmembers during missions. The issue of altered response
to drugs in space was raised as early as the pre-Skylab era, but has not been pursued
actively due to the lack of adequate analytical techniques, as well as technical feasibility
during flight. Although efforts to identify effective treatment methods for space motion
sickness (SMS) during the shuttle program h_e reactivated interest in pharmacokinetics
and pharmacodynamics in space, application of research findings in this area goes well
beyond the treatment of SMS.
The biological effect elicited by a therapeutic agent in a given dosage form under any
conditions is a function of the intrinsic activity of the agent and its concentration at the site
of action. The onset, intensity, and duration of the pharmacological response produced by
drugs, collectively known as the pharmacodynamics of an administered medication, depend
upon the processes that characterize their absorption, distribution, metabolism, and
elimination. The mathematical description of these processes and their interrelationships
are described by pharmacokinetics. Knowledge of the kinetics and dynamics of a
pharmacological agent allows (1) the design and development of an effective dosage
regimen; (2) readjustmentof that regimen to individual requirements;and (3) an
understandingof unusual pharmacologicalresponses,with correction asneeded.
The four parameters of drug pharmacokinetics are: (1) elimination half-life, the time
required for a given agent to decrease to one half of its initial concentration; (2) volume of
distribution, a proportionality constant that describes the total amount of drug in the body
relative to its plasma concentration; (3) bioavailability, the measurement of both the
relative amount of an administered dose that reaches the general circulation and the rate
at which this occurs; and (4) clearance, the virtual volume of blood or plasma cleared of
drug by all applicable organs of elimination per unit time. These pharmacokinetic
parameters are subject to variation due to a large number of biochemical, biological, and
clinical factors such as gastrointestinal, hepatic, and renal function of the subject, body
weight and size, disease state, and interaction with simultaneously administered drugs. A
list of physiological factors that affect the pharmacokinetics of drugs are presented in Table
1.
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Microgravity is known to induce changes in cardiovascular, renal, and hepatic function;
microgravity can therefore be inferred to influence drug pharmacokinetics and
pharmacodynamics. Indeed, preliminary findings with two drugs suggest that
pharmacokinetics are altered by exposure to microgravity. Understanding the
pharmacokinetic behavior of medicationsadministeredin microgravity, and thereby
allowing meanswith which to predict that behavior, however,requires the definition and
understandingof the physiologicalmechanismsunderlying thesechanges,and the sequence
in which they occur. The mostimportant aspectof pharmacokinetics in spacemedicine is
that the pharmacokineticsof a drug governthe onset,intensity, and duration of the
therapeuticactivity of that drug. Furthermore, the magnitude of pharmacodynamic
deviations as a result of pharmacokinetic changes may be different for different drugs,
depending upon their intrinsic activity and structure-activity relationship. Therefore, the
pharmacodynamics of drugs that are functionally and operationally crucial for a successful
mission must be clearly understood in order to ensure safe and effective therapeutic
intervention in space.
The Biomedical Operations and Research Branch at the Lyndon B. Johnson Space Center
has been mandated with evaluating the pharmacokinetic and pharmacodynamic
consequences of space flight and with making appropriate recommendations concerning
effective modes of administration during space flight. As a first step in fulfilling this task,
preliminary ground-based and inflight investigations have been conducted with
acetaminophen, a well-characterized pain reliever, and scopolamine, which is in
operational use as an antimotion-sickness agent. Results from these initial investigations
confirm that space flight does induce significant changes in the absorption and
bioavailability of these drugs after oral administration. These preliminary results, coupled
with the extension of space flight duration in preparation for long-term missions onboard
Space Station Freedom, prompted convening this workshop in order to discuss the
physiological and pharmacological consequences of space flight with leading experts in the
scientific community. Participants in the workshop are listed in the Appendix.
This document is a summation of presentations and discussions held at this workshop. The
first section outlines the objectives and scope of the workshop, as presented to the
participants, and offers a brief overview of workshop activities. The second section consists
of panelists' comments. The third and final section provides a summary of
recommendations.
L. Putcha, Ph.D.
Pharmacologist
Biomedical Operations and Research Branch
WORKSHOP OBJECTIVES
This workshop was organized and conducted to identify and discuss some of the major
issues of pharmacokinetics and pharmacodynamics in space medicine and seek
recommendations for research and operations from leading scientists in the field. The
specific objectives of the workshop were to accomplish the following:
o Present issues and concerns of pharmacokinetics and pharmacodynamics in space
medicine
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Solicit assistance in predicting alterations in the pharmacokinetics and
pharmacodynamics of drugs in microgravity
Identify and pnoritize research objectives and operational strategies for safe and
effective drug treatment in space
Initiate collaborative research endeavors with outside institutions
.
e
Establish ongoing consulting relationships with leading experts in the field
Prepare a reference document that defines the direction of future research and
operational issues in clinical pharmacology during space flight
WORKSHOP SCOPE
The following specific topicswere presentedfor discussion.The issueslisted under eachof
these topics were addressed in separate sessions.
Effeetof Physiolo_c Variables on Pharmacokinetic Parameters
What are the important physiologic parameters that may affect drug pharmacokinetics
in microgravity?
Does altered gastrointestinal motility affect gastrointestinal absorption?
Will bioavailability of medications differ in space?
Does drug distribution change in microgravity?
Does microgravity affect drug metabolism?
Biopharma¢¢o_ical Aspects of Space Medicine
- What kinds of dosage forms should be considered?
Do conventional formulations work?
Are specialized delivery systems feasible?
What are the optimum methods of delivery?
- What kinds of dosage regimens may be recommended?
Pharmacodynami¢$ I_sues of Clinical I m.portanc¢
Will microgravity change dose-response relationships?
Are there specific drugs that may be more sensitive to pharmacodynamic changes?
Will microgravity affect the therapeutic index of operationally crucial medications?
Methodological Issues
What methods of drug monitoring are suitable for application on the ground and in
flight?
Which methods of sample handling and analysis are suitable for space flight?
What kind of modifications to conventional research protocols are necessary in order
to gather the best possible data?
Special Areas of Concern
What flight-specific changes can be expected and how can they be identified?
Which ground-based simulation models are suitable for pharmacokinetic
investigations?
Can physiologically based pharmacokinetic and pharmacodynamic models be
developed to identify flight-induced changes?
Can these models provide information on future research directions and choice of
medications in space?
WORKSHOP OVERVIEW
The two-day conferencebeganwith openingremarksfrom Dr. Carolyn Huntoon, Director
of Life Sciencesat JohnsonSpaceCenter. The first sessionwasdevotedto a brief overview
of ongoingprograms in spacemedicine, including applicable SpaceStationsubsystems,
operational and researchapproachesto understandingthe physiological effectsof space
flight, and preliminary findings on pharmacokinetic deviations in flight. The remainder of
the conference was devoted to discussion of issues and recommendations for research and
operations programs. Each issue listed in the previous section (Workshop Scope) was
introduced by a predesignated panel member, and then opened for discussion. A synopsis
of the discussion, including the panel's recommendations for research, was presented at the
end of the symposium.
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PANELISTS' COMMENTS
Physiological Considerations of Pharmacokinefi¢ Parameters (Grant R. Wilkinson)
Drug concentrations within the body reflect the net balance between delivery/absorption,
distribution, and elimination. The independent pharmacokinetic parameters volume of
distribution and clearance quantify the distribution and elimination, respectively, of a drug
in the body. These pharmacokinetic parameters are governed by physiologic factors such
as organ size, relative binding characteristics between plasma and tissue proteins, and
organ blood flow affecting volume of distribution of a drug; organ clearance has also been
recognized as a function of blood flow, plasma binding and the intrinsic metabolic and/or
excretion activity of the organ. Since zero gravity is known to affect physiological
determinants such as cardiac output and organ blood flow, it is quite likely that a drug's
pharmacokinetics will be different in space relative to earth. Whether these alterations are
of sufficient magnitude to affect drug disposition significantly and produce a clinically
significant change in the resulting pharmacological effects (efficacy and toxicity) can be
answered only after assessing individual physiological and pharmacokinetic changes during
space flight.
A drug's availability on space missions will be determined largely by preflight predictions of
which medical or surgical situations are likely to occur. Since evaluation of clinical
pharmacology in space is not feasible, predictions will be made based upon information
collected on earth. For example, where alternative and equivalent medications are
available for the same condition, prudence dictates selection of the drug with the widest
therapeutic margin. These choices may be further refined by knowledge of the effects of
microgravity upon critical determinants of the drug's disposition. For example, if kidney
function is significantly impaired in space, then renal excretion of drugs and metabolites
would be reduced. Thus, drugs that are eliminated chiefly via urinary excretion must be
administered cautiously, with either modification of dosage in order to account for reduced
renal function, or replaced by another agent that does not depend upon urinary excretion.
Obviously, this approach requires knowledge of how zero gravity affects the physiological
determinants of disposition, and an understanding of the relative importance of these
physiological determinants in a drug's pharmacokinetics. Evaluation of candidate drugs
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must include assessments of (1) the role of renal and/or hepatic function in elimination;
(2) the role of plasma binding in distribution and/or elimination; and (3) the possibility
that modest impairment of hepatic elimination may produce a significant oral-dose "first-
pass" effect.
It is well known that any measured pharmacokinetic parameter is the result of interactions
among physiological factors, such as drug-metabolizing enzymes and transport processes,
and properties of a specific drug, such as binding to plasma and tissue proteins. It is
unlikely that mierogravity changes a drug's thermodynamic properties relative to 1 g. More
likely, any pharmacokinetic changes in space would result from biological changes such as
alterations in protein or enzyme levels. Accordingly, space-related alterations in
disposition could be predicted with knowledge of how microgravity affects physiological
determinants. This physiological modeling approach has been used successfully in the
laboratory where perturbations have occurred in the determinants.
Sufficient information is not currently available for physiologic modeling. Animal studies
may prove useful; comparison of the few microgravity data available with results from
simulated model systems is also necessary. This process is not unlike evaluation of a new
candidate drug for use in humans. The goals in both approaches cannot be precise
prediction, but rather an assessment of likelihood that a given regimen will provide an
acceptable level of risk-benefit.
Rapid and efficient collection of the necessary physiological information can be achieved
using the following experimental approaches:
Renal function. The renal excretion of all drugs is in almost all instances proportional to
the glomerular filtration rate (GFR). Accordingly, data on the extent of any change in this
function under simulated zero-gravity conditions would be broadly applicable. If significant
impairment is present, then dosages could be modified according to pharmacokineticaUy
based procedures established and validated in patients with compromised kidney function.
Since zero gravity is known to alter muscle mass, an absolute measure of GFR should be
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used, rather than one based on ereatinine clearance. Also, since the techniques are fairly
simple, consideration should be given to obtaining this information in astronauts under
zero gravity.
Drug-m¢Iabolizing e _nzyme activities. The biotransformation of a drug involves many
enzymes and isozymes. It is impossible to evaluate the effects of zero gravity on every
enzyme and isozyme with respect to the metabolism of a large number of specific drugs,
particularly in rive. The most practical approach appears to be an assessment of the
magnitude of any changes in selected metabolic pathways in vitro. Thus, rats would be
exposed to simulated or zero gravity, sacrificed and the liver removed in order to prepare a
suitable in vitro metabolizing system (9000 g supernate, microsomes, etc.) for further study
at 1 g. Reactions to be screened would use a variety of conventional substrates that are
oxidized by the monooxygenase system(s), glucuronidation, sulfation, and acetylation. An
alternative, perhaps more feasible approach that has direct applicability to evaluating
changes in drug-metabolizing activity in astronauts during space flight would be to use
probe drugs to elucidate the activity of specific enzymes. Techniques exist to allow ready
noninvasive measurement of enzyme activity, especially monoxygenation, by analyzing a
single timed urine sample after oral drug administration. Comparing enzyme activity in 1-g
to that in true or simulated zero gravity would allow evaluation of the effect of space flight
on metabolizing activity. Zero gravity may have only modest effects on metabolism;
however, the potential for major changes must be assessed. If zero gravity induces a
selective effect, such as impaired oxidation without affecting conjugation, then alternative
medications may be indicated for use in space (e.g., substituting oxazepam for diazepam).
Cardiac output and organ blood flow. Drug distribution and delivery to the organs of
elimination is dependent upon blood flow, and thus depends upon cardiac output. A
simple, direct study of the effects of space flight on these cardiovascular parameters would
involve injecting rats in flight with a bolus of radiolabelled microspheres. After a short (15
min) single blood-sampling period, the animals would be sacrificed and various tissues
analyzed after return to Earth.
Organ _ize. Fluid redistribution is a well-described effect of microgravity. Fluid
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redistribution leads to changes in organ size, which in turn could affect drug distribution.
Information could be obtained from the preceding microsphere study on alterations in
organ weights. (It may be important to evaluate the effect of increasing length of time in
microgravity on organ weight, with the caveat that the adaptation period for animals is
probably different than that for humans). After data collection, physiological modeling can
be applied in which simulations using drugs with critical pharmacokinetic characteristics
could then be performed and an assessment of integrated effects of individual changes
made. Finally, an in vivo validation of the predicted pharmacokinetics in zero gravity may
be required.
In each experimental approach, of paramount importance is assessment of the magnitude
of change in zero gravity, and evaluation of whether a change is large enough to cause
significant changes in drug disposition and effects. While large interindividual differences
in pharmaeokinetics exist at 1g, this generally has little effect on successful clinical use of
the drug. If such variability is 4- to 10-fold, a not unusual range for drug metabolizing
activity, one must bear in mind that a statistically significant 30% change induced in
microgravity may not ultimately affect clinical efficacy.
The focus of this section has been limited to the pharmacokinetic aspects of drug effects.
Pharmacodynamics are also of critical importance, and must be rigorously addressed. In
fact, it may be that pharmacodynamics, in combination with drug delivery, are primarily
responsible for altered clinical responsiveness in zero gravity. Of particular concern in this
respect are drugs that elicit their effects by way of homeostatic mechanisms. Set points
within the cardiovascular-renal systems are known to be altered by zero gravity, as well as
down- and up-regulation of certain physiological receptors. It would be surprising if these
adaptations did not alter drug responsiveness.
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Pharrna¢okinotic Cor_idcr_tions of Space Flight (Leslie Z. Benet)
Primary concern should be directed to the four major pharmacokinetic variables that can
be used to evaluate drug kinetics. That is, clearance, a measure of the body's ability to
eliminate a drug; volume of distribution, the space available in the body into which the
drug may distribute; half-life, a dependent variable that changes inversely with clearance
and directly with volume of distribution, but is useful as a measure of the appropriate
dosing interval for drugs; and bioavailability, a measure of both the rate and extent by
which drugs are made available to the systemic circulation following dose administration.
All of these parameters could potentially change in space. Preliminary studies with
acetaminophen and scopolamine have demonstrated that rates and possibly extent of
absorption may vary when the saliva concentration profiles of these drugs are compared
with preflight profiles. Rate of availability may be the most variable parameter noted in
space, since gastrointestinal transit time and absorption of some drugs is known to change
markedly depending on body position.
Few of the physiologic changes associated with short-term and long-term space flight allow
quantitative prediction of changes in the other three primary pharmacokinetic parameters,
clearance, volume of distribution, and half-life. Decreased urine volume early in flight and
decreased uric acid excretion may indicate a reduced ability to pass drugs into the urine,
resulting in decreased drug renal clearance. The stress related to space flight could result
in increases in a-l-acid glycoprotein, which could result in increased protein binding of
basic drugs, which could in turn produce decreased volume of distribution and clearance
for such compounds. The increase in stroke volume, cardiac output, and heart rate, as well
as the marked decrease noted in leg blood flow in flight, suggests that blood flow to various
regions of the body may be altered; thus high-extraction ratio drugs may be expected to
show an increase in clearance in flight corresponding to increased blood flow, when this is a
rate-limiting factor.
Body composition changes during the first month in flight (losses of water, protein and fat)
could lead to distribution changes; however, without further information concerning the
relative changes in these three basic body components, it is difficult to predict whether
significant changes would occur. Since there are no good non-drug markers for subjects not
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in flight, the physiologic parameters measured are not expected to be predictive of changes
in drug metabolism; therefore it is difficult to predict whether metabolic processes change
in flight.
At this point, very little information is available about the pharmacokinetics of drugs in
space, except for the high variability in rates of drug absorption. It is unclear from the data
presented whether even the extent of absorption changes markedly. A number of well-
designed studies are required before important questions can be answered concerning the
possibility of marked change in drug kinetics leading to differences in pharmacodynamics
which could ultimately result in reduced efficacy or other adverse effects.
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Drug Absorption in Micro_avity (Gordon L. Amidon)
Preliminary studies of salivary drug-concentration time curves in space indicate that the
absorption of acetaminophen and scopolamine is highly variable in microgravity. The
extent of drug absorption depends upon intestinal membrane permeability and
gastrointestinal transit time; a drug's systemic availability also depends upon first-pass
metabolism in the gastrointestinal tract and liver. The kinetics of drug absorption depend
upon rate of gastric emptying (particularly for drugs with high intestinal-membrane
permeability such as acetaminophen or scopolamine), varying intestinal-membrane
permeability at different locations along the GI tract, and overall gastrointestinal transit
time. In addition, the kinetics of drug metabolism by the liver will determine whether
systemic availability of a particular drug is dose-rate dependent. All of these parameters
can change in microgravity. Some considerations related to each of these possibilities are
offered below.
Gastric emptying, i,e., the rate at which a substance leaves the stomach and enters the
intestine (the primary absorptive site), is dependent upon the motility of the
gastrointestinal tract. This motility, which is marked by phases, is distinctly different in
fasted vs fed subjects. In dogs and in humans, the fasted state is characterized by cyclical
intestinal motility and thus highly variable gastric emptying. Gastric emptying is slowest in
phase I (quiescent phase), somewhat faster in phase II (intermittent contractile activity)
and fastest in phase III (regular, strong contractions). This contractile activity cycles every
two hours, with contractions propagating from the stomach down the intestine to the
ileocecal region. For drugs with high membrane permeability, therefore, gastric emptying
and drug absorption can be affected by changes in the length of the individual phases as
well as the length of the cycle as a whole. In addition, tablets and capsules require contact
between the dosage form and digestive fluids in order to disintegrate and dissolve. In
microgravity, both the contact between the dosage form and the fluids, and the emptying of
the combined substance through the pylorus, may be different than in 1-g.
The gastric emptying pattern in the fed state differs significantly from that of the fasted
state, depending primarily on the number of calories in a meal. Liquid ingested with a
meal empties relatively rapidly over 30 to 60 minutes. The solid component of the meal is
broken down gradually through the mechanical action of contractions in the stomach
combined with fluid, acid and enzyme secretions. Extensive studies in dogs indicate that
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90% of the food particles leaving the stomach are less than 0.5 mm in size. Small particles
(less than 1 mm) empty relatively rapidly with the liquid component of the meal, while
larger spheres empty more slowly. Panicles larger than 4 to 5 mm in diameter empty at the
end of the meal, with the reappearance of phase III contractions marking the transition to
the fasted-state motility pattern. Extensive studies in dogs and humans have indicated that
panicles of approximately 1.5 mm in diameter empty on the average at the same rate as the
solid component of the meal. It is believed that this particle size is necessary to suspend a
substance in fluid and to increase its surface area for efficient digestion.
Gastric emptying is dependent on particle size, particle density, and fluid viscosity. Simple
fluid-mechanical considerations suggest that gastric emptying is determined by either the
ratio of buoyancy force to drag force, or equivalently, the ratio of the Stokes settling
velocity to mean fluid velocity. Consequently, gravity is intimately involved in controlling
the emptying of particles from the stomach. There is a very high probability that gastric
emptying in the fed state will be altered significantly in microgravity. The implications of
these changes include not only changes in drug absorption but also changes in nutrient
absorption and intestinal adaptation. For example, in a normal intestine, food is
completely digested and absorbed by mid-gut. However, if food of a larger particle size
empties from the stomach, digestion will take longer. It is well known that the intestine
adapts to the presence of particular nutrients. Consequently, gastrointestinal motility in
microgravity may slow via feedback from the intestine itself; the localized permeability of
the intestinal membrane may also change.
In addition to drug absorption and portal-system availability, f'trst-pass metabolism can
significantly alter the systemic availability of active drugs. The absorption of some drugs
such as propranolol and verapamil is dose-rate dependent. Furthermore, the isomer ratios
of drugs can be dose-rate dependent if the individual isomers have different metabolic rate
constants in the liver. Consequently, the systemic variability of an active drug can be
affected by the input-rate dependence of liver metabolism. Consequently, the variability of
a drug's plasma level associated with variable gastric emptying can be exaggerated through
nonlinearity in metabolism. It is possible that the demonstrated variation in plasma levels
of scopolamine and its varied effectiveness during space flight may be related to this
mechanism.
Finally, the frequent occurrence of space motion sickness clearly alters gastrointestinal
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function and drug absorption. Loss of appetite for several days or more also indicates
significant alterations in gastrointestinal transit. While the mechanisms of these responses
are not well understood, they provide additional evidence that gastrointestinal function is
altered in microgravity. The duration of these changes should be studied in flight in order
to determine the differences in gastrointestinal-tract function in microgravity compared to
its function in l-g, and to determine when the gastrointestinal tract adapts to microgravity.
Preliminary results clearly indicate that gastrointestinal functioning is significantly altered
in space. This change in function will influence drug absorption through its effect on
gastric emptying and intestinal transit as well as indirectly through the effects of dose rate
on liver metabolism for drugs that exhibit nonlinear first-pass metabolism. Studies should
be designed to measure gastric emptying and intestinal transit in both fasted and fed states
in microgravity. Given the high degree of variability, studies should be conducted in the
same individuals before flight, several times during flight, and after flight. Studies with
drugs such as acetaminophen, aspirin and scopolamine as well as intestinal-transit markers
such as lactulose may be used to measure the effects of gravity on both gastric emptying
and intestinal transit. Such studies are not only fundamental to providing adequate drug
therapy in space, but also may be valuable in designing appropriate types of nutrition in
order to maintain high performance levels in microgravity.
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Ph_rmacodvnamic Aspects of Space Flight (Gerhard Levy)
The pharmacologic response to medications may be altered during and for some time
following space flight and exposure to rnicrogravity. This alteration would be expected to
be quantitative rather than qualitative. It is likely to be caused by, or associated with, the
pronounced physiologic changes that are being experienced during space flight, including
those of cardiovascular function, neurovestibular performance, body water distribution,
organ perfusion, and electrolyte concentrations. These changes may affect the
pharmacokinetics as well as the pharmacodynamics of drugs. Pharmacokinetics pertains to
the rates and rate constants of processes of drug absorption, distribution, metabolism and
excretion, whereas the term pharmacodynamics, as used in this discussion, refers to the
relationship between intensity of pharmacologic effects of medications and the
concentrations of these medications and their active metabolites in the biophase (i.e., in
the immediate environment of the site of action) or in fluids or tissues that reflect the
biophasic concentrations.
Much is known about the processes that constitute the pharmacokinetic characteristics of
drugs, including the molecular basis of xenobiotic transport and biotransformation.
Conversely, much less is known about the mechanisms by which drugs elicit their desired
and adverse pharmacologic effects. Particularly, post-receptor events that cause the
ultimate expression of a ligand-recognition site interaction into clinically apparent effects
remain to be fully elucidated. This limits severely our ability to predict the
pharmacodynamic changes that may occur during space flight. On the positive side,
however, it is likely that most if not all such changes will not be caused by mierogravity per
se, but by the physiologic perturbations that arise due to exposure to mierogravity. These
perturbations can be reproduced in a terrestrial setting, particularly in experimental
animals but also to some degree in humans, and are therefore amenable to investigation
under controlled conditions in normal laboratory or clinical environments.
The first principle in these studies, as well as in studies during space flight, is to make a
clear distinction, both intellectually and practically, between pharmacokinetics and
pharmacodynamics. Altered dose-response relationships may be due to altered
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pharmacokinetic or pharmacodynamic characteristics, or both. Thus, the dose-response
relationship is a hybrid, one that can lead to considerable confusion. It must be dissected
into its dose-concentration and concentration-effect components.
Another important consideration, one that can account for considerable intra- as well as
interindividual variation in the pharmacologic response to medications taken during space
flight, is that the intensity of the pharmacologic response (effect) may be modified by stress,
lack of sleep, changes in chronophysiologic status and other such factors in addition to the
physiologic changes directly associated with microgravity. This implies the need for flexible
drug dosage, inflight assessment of therapeutic response, and dosage titration based on that
response.
Considering the fact that the physiologic perturbations due to microgravity do not arise
instantaneously but develop over hours, days or weeks, it is to be expected that the effects
of certain medications on erewmembers during space flight will change with time. It should
be possible, however, at least in principle, to assess such time dependencies under
experimental conditions on Earth. To the degree that medications will be taken by
astronauts in space for experimental or therapeutic purposes, and that drug kinetics and/or
dynamics will be measured under these conditions, it is highly desirable that they be
preceded by and followed by at least one, preferably several, replications on Earth in order
to assess intra-individual variation of parameter values. In view of the heavy work load of
flight crews, and the presumed low priority and difficulty of performing meaningful
pharmacokinetic-pharmacodynamic experiments on humans in space, serious thought
should be given to in-flight animal experiments, with particular attention directed to the
period immediately after flight, while alterations in physiologic status persist. Many of
these studies can be performed on rodents, in conjunction with experiments under
conditions of simulated weightlessness.
It is presumed that the crucial systemic medications for prolonged space missions (1 to 12
months) include antibiotics and other antiinfeetives (including those for the urinary and
gastrointestinal tracts), analgesics, antiarrhythmics and other drugs acting on the
cardiovascular system (particularly on blood pressure), hypnotics, stimulants, steroids (as
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both antiinflammatory and antistress agents), a histamine H2-receptor antagonist, an
antihistamine, an antiemetic, perhaps medication to prevent nephrolithiasis, and a blood
volume expander. Of these agents, particular attention should be directed to drugs that act
on the central nervous system, and therefore have the potential of affecting crew
performance: hypnotics, stimulants, analgesics, antihistamines, and antiemetics such as
scopolamine. It is necessary even on Earth to carefully titrate antiarrhythmic medication,
so experimental investigations may be of limited predictive usefulness. Antibiotics are
likely to present the fewest problems in terms of adverse effects (only a few antibiotics have
potentially serious side effects) and efficacy (clinical concentrations are usually well above
the minimum effective concentration).
It is recommended that initial studies be performed on rodents under conditions of
simulated weightlessness. These studies should involve standard tests for CNS functionality
such as rotarod, loss of righting-reflex activity, neurotoxieity (seizure threshold), maze
performance, pain sensitivity (tail flick, electroshock) and analgesic response in association
with drug concentration determinations. Test drugs for these initial studies should include
an amphetamine, a barbiturate, a benzodiazepine, morphine, a nonnarcotic analgesic,
scopolamine, cimetidine or ranitidine, and an antihistamine. Clinical studies in human
volunteers during or after prolonged head-down bed rest can focus on the effect of these
medications on hand-eye coordination, memory, arithmetic skill and other standard CNS
performance tests.
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Research Methodologies (Jerry Collins)
There are some special challenges for pharmacology studies in space. Yesterday, Stuart
Feldman said our two goals were the search for new knowledge and for specific answers in
order to treat individuals in specific situations. For modeling, we could restate the goals as
individual-oriented or population-oriented. I would say that there are three distinct steps:
The first, knowing the ground-based model that describes pharmacokinetics; the second,
revising the model for space in light of mean values; and the third, individual modeling.
Computers play a role in all these steps. Micros, minis and mainframes can all work with
all but the largest programs, since software has the dominant role. The two types of
program applications are simulations and parameter estimation. In my experience, there
are no universally accepted software packages, although several exist that have attractive
features and are technically satisfactory. Simulation programs are less complex and less
demanding than parameter estimation routines. Simulation programs, especially for
physiologic pharmacokinetic models, allow the investigator to ask "What if...?" As Benet,
Levy, and Wilkinson all noted yesterday, a straightforward approach would be to build a
baseline physiologic model, then alter a parameter and find out what happens if cardiac
output is redistributed. But, as noted yesterday, we do not have the database to decide how
much to change the parameters. Also, although there are advantages to examining one
critical variable, one should beware of over-simplified models that do not permit the
investigator to see interactions among kinetic parameters.
Parameter estimation is fundamentally a process of collecting experimental data and
plugging it into a computer program. However, no data should be entered into such a
program without prior graphical analysis. Some data sets should never be subjected to
computer analysis. If the graphical pattern is incompatible with the model assumptions,
parameter estimation will be meaningless no matter how many digits are printed out.
Excellent programs are available to guide experimental design so as to minimize the
number of samples per subject, a true constraint on most missions. NONMEM is one of
these. However, these programs will not work well with the acetaminophen and
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scopolamine data sets if ground-based models are used. Traditional model-definition
studies must be done in the space environment for operationally significant drugs or model
compounds. NONLIN, MLAB, SAAM, SIMUSDLV, and many other programs are quite
adequate.
Finally, the link between kinetics and dynamics is always a key issue in pharmacologic
studies, although this goal is often slighted, resulting in poor understanding of this link in
many clinically used drugs. Experimental design is crucial in all cases, but especially when
observations are limited. Continuous drug delivery systems greatly simplify this area and
should be pursued. In particular, reevaluation of transdermal scopolamine should receive
high priority.
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SUMMARY AND RECOMMENDATIONS
The panel recommended that pharmacodynamic studies be conducted in four distinct but
overlapping phases:
Ground-based animal models (e.g., hindlimb-suspended rats)
Ground-based 0-g simulation with human subjects (e.g., head-down bed rest)
In-flight and postflight monitoring of pharmacological responses to well-
characterized medication in animals
Preflight, inflight, and postflight pharmacodynamic and clinical studies in humans
It was emphasized that because clearance, volume, half-life, and bioavailability all
contribute to changes in pharmacokinetics, all should be evaluated. The following
variables were identified as crucial to the understanding of pharmacokinetic and dynamic
changes during flight: organ perfusion rates; hydration state and fluid distribution; renal
function, as reflected by plasma protein and urine composition, volume and pH; blood
pressure; drug-metabolizing enzyme activity; and circadian and diurnal variations. The
magnitude of these and other physiological changes must be determined in order to
determine whether they are large enough to affect mode of drug delivery. Furthermore,
because physiological adaptation to mierogravity is probably expressed differently in
different erewmembers, intersubject variability must be taken into account during both
ground-based flight simulation studies and in-flight studies.
Ground-based studies. The panel felt that identifying an appropriate ground-based model
that reflects a number of mierogravity-induced changes should be the immediate task.
This model should be validated with drugs that will be used in flight. Such a model would
be useful for the next 10 to 20 years. Information from ground-based studies, including
steady-state animal data, can be used to derive physiological models; however, parameters
to be modeled must be selected carefully. The pharmacokinetic computer programs
NONLIN, NONMEM, ADAP, or other programs can be used for data analysis on
mainframes or on PCs. Identifying spaceflight-related changes in plasma-to-tissue
partitioning coefficients, distribution, and excretion can be accomplished using animal
models. Salivary flow dynamics and composition should be evaluated in order to validate
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the saliva sampling method in space.
In-flight studies. In order to assess the pharmacodynamic consequences of microgravity,
data on drug action vs. drug concentration must be collected during flight. Investigators
must collaborate in designing sample collection strategies, so that the limited opportunities
for collecting in-flight data can be useful to the greatest number of investigators.
Collecting medical information from previous US and Soviet flights is strongly
recommended in order to better understand the behavior of some of the medications
administered during flight.
Dru_. Concerning the selection of drugs for study, the panel recommended
studying first those drugs with a narrow therapeutic index that are likely to be used in flight,
such as some cardiovascular drugs. Microgravity-induced changes in the absorption and
metabolism of such drugs would pose the greatest risk to crewmembers during flight. The
protein-binding characteristics of these drugs should be thoroughly characterized, and data
collected after landing as well as during flight. Procedurally, it was suggested that Phase I
to Phase IV IND protocols be developed for drugs that are to be used by crewmembers
during flight. During discussions of specific drugs, the point was raised that absorption and
metabolism of acetaminophen reflects the functioning of but a single enzyme system; other
enzyme systems should also be evaluated. Bed rest can be used to evaluate changes in
rapidly cleared drugs such as lidocaine. Antipyrinewas proposed as a test compound that
can illustrate fluid distribution patterns as well as metabolic function. It was suggested that
multiple doses of stable labeled compounds could be used to monitor drug metabolism and
distribution during flight. The general consensus of the panel concerning selection of drugs
for study in flight was to use those drugs with a wide therapeutic margin whenever they are
available, so that unforeseen therapeutic consequences due to flight-induced physiological
changes can be avoided.
Dosage forms. Liquid dosage was considered the best form for in-flight drug delivery;
however, it was acknowledged that motion sickness may interfere with the effectiveness of
oral administration. Other potential dosage forms include oral strips or granules;
suppositories; nasal drops or sprays; transdermal unit-dose delivery systems; and
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intramuscular injections. These forms should be tested during bed rest before
implementation during flight.
Finally, the panel recommended addressing the following research questions: (1)
differentiating intrinsic vs. flow-limited changes in liver metabolism during space flight; (2)
determining hepatic extraction as a function of perfusion, oxygenation and hematocrit; and
(3) determining the effect of glomerular filtration rate on rate of excretion. These factors
must be evaluated on a drug by drug basis, using drugs with a narrow therapeutic index.
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